In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases

Pharmacotherapy

Volumn 34, Issue 2, 2014, Pages 114-122

  Joy, Melanie S ^a,b   Frye, Reginald F ^b   Nolin, Thomas D ^c   Roberts, Brittney V ^a   La, Mary K ^d   Wang, Jinzhao ^d   Brouwer, Kim L R ^e   Dooley, Mary Anne ^d   Falk, Ronald J ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Pharmaceutical Sciences Department   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e University of North Carolina   (United States)

Author keywords

CYP2C9; CYP3A4; Glomerulonephritis; Lupus nephritis; P glycoprotein; Single dose pharmacokinetics; Small vessel vasculitis

Indexed keywords

4 HYDROXYFLURBRIPROFEN; ARYLPROPIONIC ACID DERIVATIVE; CARBON 13; CARBON 14; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ERYTHROMYCIN; FEXOFENADINE; FLURBIPROFEN; UNCLASSIFIED DRUG; 4'-HYDROXYFLURBIPROFEN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATH ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GLOMERULONEPHRITIS; HUMAN; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN FUNCTION; URINALYSIS; AGED; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; BREATH TESTS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; FEMALE; FLURBIPROFEN; GLOMERULONEPHRITIS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TERFENADINE; YOUNG ADULT;

EID: 84898032840     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1347     Document Type: Article

References (42)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298: 2038-47.
2. System, USRD. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
3. Guevin C, Michaud J, Naud J, Leblond FA, Pichette V. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002;137: 1039-46.
4. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 2008;36: 124-8.
5. Simard E, Naud J, Michaud J, et al. Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 2008;19: 1352-9.
6. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109: 1-11.
7. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83: 898-903.
8. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5 + 1 cocktail." Clin Pharmacol Ther 2003;74: 437-47.
9. Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther 2006;80: 257-63.
10. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62: 365-76.
11. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006;17: 2363-7.
12. Dreisbach AW, Japa S, Gebrekal AB, et al. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther 2003;73: 475-7.
13. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003;73: 427-34.
14. Kim YG, Shin JG, Shin SG, et al. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 1993;54: 612-20.
15. Manley HJ, Garvin CG, Drayer DK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 2004;19: 1842-8.
16. Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol 2010;50: 714-20.
17. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 2004;20: 195-217.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41.
19. Nolin TD, Frye RF, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009;20: 2269-76.
20. Cefali EA, Poynor WJ, Sica D, Cox S. Pharmacokinetic comparison of flurbiprofen in end-stage renal disease subjects and subjects with normal renal function. J Clin Pharmacol 1991;31: 808-14.
21. Stanton ML, Joy MS, Frye RF. Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878: 497-501.
22. Ellis D, Buffone GJ. Protein clearances and selectivity determinations in childhood nephrosis: a reappraisal. Clin Chem 1981;27: 1397-400.
23. Joy MS, Hilliard T, Hu Y, et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy 2009;29: 7-16.
24. Joy MS, Gipson DS, Dike M, et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 2009;4: 39-47.
25. Joy MS, Hilliard T, Hu Y, et al. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother 2009;43: 1020-7.
26. Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006;79: 218-30.
27. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33: 963-8.
28. Xie R, Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St. John's Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005;45: 352-6.
29. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9: 215-36.
30. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2008;36: 663-9.
31. Shimizu M, Fuse K, Okudaira K, et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 2005;33: 1477-81.
32. Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistanceassociated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 2008;36: 911-5.
33. Tian X, Zamek-Gliszczynski MJ, Li J, et al. Multidrug resistance- associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 2008;36: 61-4.
34. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45: 525-38.
35. Hooper WD, Bochner F, Eadie MJ, Tyrer JH. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974;15: 276-82.
36. Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984;9(Suppl 1): 18-26.
37. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57: 16-24.
38. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002;72: 718-28.
39. Burstein AH, Reiss WG, Kantor E, Anderson GD. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta-hydroxycortisol:cortisol ratios. Pharmacotherapy 1998;18: 1271-6.
40. Aitken AE, Richardson TA, Morgan ET. Regulation of drugmetabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006;46: 123-49.
41. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001;29: 207-12.
42. Frassetto LA, Poon S, Tsourounis C, Valera C, Benet LZ. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 2007;81: 828-32.